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Identifi cation of new susceptibility loci for osteoarthritis 
(arcOGEN): a genome-wide association study
arcOGEN Consortium and arcOGEN Collaborators*
Summary
Background Osteoarthritis is the most common form of arthritis worldwide and is a major cause of pain and disability 
in elderly people. The health economic burden of osteoarthritis is increasing commensurate with obesity prevalence 
and longevity. Osteoarthritis has a strong genetic component but the success of previous genetic studies has been 
restricted due to insuffi  cient sample sizes and phenotype heterogeneity.
Methods We undertook a large genome-wide association study (GWAS) in 7410 unrelated and retrospectively and 
prospectively selected patients with severe osteoarthritis in the arcOGEN study, 80% of whom had undergone total 
joint replacement, and 11 009 unrelated controls from the UK. We replicated the most promising signals in an 
independent set of up to 7473 cases and 42 938 controls, from studies in Iceland, Estonia, the Netherlands, and the 
UK. All patients and controls were of European descent.
Findings We identifi ed fi ve genome-wide signifi cant loci (binomial test p≤5·0×10–⁸) for association with osteoarthritis 
and three loci just below this threshold. The strongest association was on chromosome 3 with rs6976 (odds ratio 1·12 
[95% CI 1·08–1·16]; p=7·24×10–¹¹), which is in perfect linkage disequilibrium with rs11177. This SNP encodes a 
missense polymorphism within the nucleostemin-encoding gene GNL3. Levels of nucleostemin were raised in 
chondrocytes from patients with osteoarthritis in functional studies. Other signifi cant loci were on chromosome 9 
close to ASTN2, chromosome 6 between FILIP1 and SENP6, chromosome 12 close to KLHDC5 and PTHLH, and in 
another region of chromosome 12 close to CHST11. One of the signals close to genome-wide signifi cance was within 
the FTO gene, which is involved in regulation of bodyweight—a strong risk factor for osteoarthritis. All risk variants 
were common in frequency and exerted small eff ects.
Interpretation Our fi ndings provide insight into the genetics of arthritis and identify new pathways that might be 
amenable to future therapeutic intervention.
Funding arcOGEN was funded by a special purpose grant from Arthritis Research UK.
Introduction
Osteoarthritis is the most common form of arthritis 
worldwide, aff ecting about 40% of people older than 
70 years.1 It is a complex disease of the musculoskeletal 
system with both genetic and environmental risk factors.2 
From the results of heritability studies in twins, sibling 
pairs, and families, genetic factors are estimated to 
account for about 50% of the risk of developing osteo-
arthritis in the hip or knee, although precise estimates 
vary according to sex, aff ected site, and severity of 
disease.3,4 Despite extensive eff orts, only three loci 
(GDF5, chromosome 7q22, and MCF2L)5–11 have thus far 
been associated with osteoarthritis at genome-wide 
signifi cance levels (p≤5·0×10–⁸) in European populations. 
This lack of success in osteoarthritis might be attributed 
to several factors such as insuffi  cient sample sizes in 
previous studies and disease hetero geneity that might 
result from diff erent underlying causes, both genetic and 
environmental, depending on which joints are aff ected.4 
The three established osteoarthritis loci have fairly small 
eff ect sizes (allele-wise odds ratios [OR] of about 1·15) 
and we have previously shown that the genetic basis of 
osteoarthritis is likely to consist of several signals of 
similar or smaller magnitude that necessitate large 
sample sizes for their detection at genome-wide sig-
nifi cance levels.12 Pheno type defi nition in cases and 
controls is also a likely factor contributing to the dilution 
of power to detect strong signals. Improved defi nition of 
phenotype and reduced misclassifi cation in such a 
prevalent disorder can enhance power.
To identify additional loci that confer susceptibility 
to osteoarthritis, we undertook a large well powered 
genome-wide association study (GWAS) of osteo-
arthritis within the context of the Arthritis Research 
UK Osteoarthritis Genetics (arcOGEN) Consortium. In 
2011, we reported the results of an interim analysis of 
43·8% of the full GWAS sample size, detecting no 
novel loci for osteoarthritis, but showing the polygenic 
nature of the disease’s underlying genetics.12 Here, we 
report the results of the full-scale arcOGEN GWAS.
Methods
Study population
We undertook a large case–control genome-wide associ-
ation study (GWAS) in which 7410 unrelated patients 
were retrospectively and prospectively selected from 
hospitals and clinics, with about 80% of patients 
ascertained for the severe endpoint of total joint 
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replacement [TJR]), and publicly available data were 
obtained from 11 009 unrelated controls from the UK’s 
Wellcome Trust Case Control Consortium 2 (WTCCC2), 
Avon Longitudinal Study of Parents and Children, Type 1 
Diabetes Genetics Consortium, and People of the British 
Isles studies (table 1; appendix p 2). We replicated the 
most promising signals in an independent set of up to 
7473 cases and 42 938 controls from studies in Iceland 
(deCODE), Estonia (Estonian Genome Centre of Uni-
versity of Tartu [EGCUT]), the Netherlands (Genetics 
OsteoArthritis and Progression [GARP], Rotterdam study 
RSI and RSII cohorts), and the UK (TwinsUK). All 
patients and controls were of European descent. For 
further details, see appendix pp 4–5.
Procedures
The arcOGEN samples were genotyped by use of Illumina 
Human 610-Quad BeadChips (Illumina, San Diego, CA, 
USA; appendix p 2). Most cases had primary osteoarthritis 
requiring joint replacement of the hip or knee (table 1). 
We did quality-control checks both at the sample and 
single nucleotide polymorphism (SNP) levels (appendix 
p 2). We did a case–control analysis for an overlapping set 
of 485 491 autosomal SNPs in 7410 arcOGEN cases of 
osteoarthritis and 11 009 controls (table 1; appendix p 2, 
p 73). We imputed genotypes for autosomal SNPs by use 
of the directly typed data and phased genotype data from 
all HapMap III populations but did not see any additional 
signals (p<10–⁵) arising from imputed SNPs that were 
not captured by the directly genotyped SNP analyses 
(appendix p 3, p 6). To assess the eff ect of phenotype 
misclassifi cation in controls, we also analysed genome-
wide genotypes in 4476 female cases of osteoarthritis 
from arcOGEN compared with 1828 osteoarthritis-free 
female controls from the TwinsUK dataset. We used a 
multiplicative model for the analysis of all data and also 
stratifi ed by site of osteoarthritis, sex, and osteoarthritis 
severity—ie, only cases with TJR were assessed (for a total 
of 24 specifi c phenotypes). We have presented the results 
for all analyses in the appendix pp 81–98, and for the most 
signifi cant specifi c phenotype in the main text. 
129 prioritised SNPs (p<10–⁵) were followed up by in-silico 
replication in the studies deCODE, EGCUT, GARP, 
Rotterdam study RSI and RSII cohorts, and TwinsUK 
(total in-silico replication sample size of 5064 cases of 
osteoarthritis and 40 619 controls). We subsequently 
undertook a de-novo replication of the 26 most signifi cant 
SNPs in an additional independent set of 2409 arcOGEN 
cases of osteoarthritis and 2319 WTCCC2 population-
based controls (UK repli cation). For our primary analysis, 
we used a meta-analysis framework to combine results 
for all data (discovery and replication) by use of a fi xed-
eff ects model (appendix p 5).
We used RT-PCR to assess the expression of at least 
one gene per signal in joint tissues from patients with 
osteoarthritis who were undergoing TJR, and in cartilage 
from individuals without clinical osteoarthritis. We 
investigated the expression patterns of nucleostemin, 
encoded by the GNL3 gene, through immuno-
histochemical staining of normal and osteoarthritic 
See Online for appendix
Study 
description
Country of 
origin
Number 
of SNPs
Cases Controls Eff ective 
sample 
size
Number Women Radiography Joint 
replacement
Hip Knee Hip and 
knee
Defi nition Number Women
arcOGEN Discovery UK 485 491 7410 4476 
(60·4%)
1606 (21·7%) 5804 
(78·3%)
3266 
(44·1%)
3498 
(47·2%)
646 
(8·7%)
Population* 11 009 5515 
(50·1%)
17 716
arcOGEN Discovery UK 532 234 4476 4476 
(100%)
1113 (24·9%) 3363 
(75·1%)
1934 
(43·2%)
2135 
(47·7%)
407 
(9·1%)
Osteoarthritis 
free
1828 1828 
(100%)
5192
deCODE In silico Iceland 128 2031 1179 
(58·1%)
0 2031 
(100%)
1269 
(62·5%)
636 
(31·3%)
126 
(6·2%)
Osteoarthritis 
free
31 487 17 209 
(54·7%)
3055
EGCUT In silico Estonia 80 213 159 
(74·6%)
NA NA 64 
(30·0%)
123 
(57·7%)
26 
(12·2%)
Population 2531 1426 
(56·3%)
786
GARP In silico Netherlands 128 215 170 
(79·1%)
169 (78·6%) 46 
(21·4%)
67 
(31·2%)
109 
(50·7%)
39 
(18·1%)
Population 1670 925 
(55·4%)
762
RSI In silico Netherlands 129 1950 1353 
(69·4%)
1628 (83·5%) 322 
(16·5%)
458 
(23·5%)
1179 
(60·5%)
313 
(16·1%)
KL<2 3243 1642 
(50·6%)
4871
RSII In silico Netherlands 129 485 306 
(63·1%)
398 (82·1%) 87 
(17·9%)
116 
(23·9%)
326 
(67·2%)
43 
(8·9%)
KL<2 1460 752 
(51·5%)
1456
TwinsUK In silico UK 129 170 170 
(100%)
170 (100%) 0 57 
(33·5%)
102 
(60·0%)
11 
(6·5%)
KL<2 228 228 
(100%)
390
UK 
replication
De novo UK 24 2409 1453 
(60·3%)
392 (16·3%) 2017 
(83·7%)
1032 
(42·8%)
1170 
(48·6%)
207 
(8·6%)
Population 2319 334 
(14·4%)
4726
Data are number (%), unless otherwise indicated. SNP=single nucleotide polymorphism. arcOGEN=Arthritis Research UK Osteoarthritis Genetics. EGCUT=Estonian Genome Centre of University of Tartu. 
NA=not available. GARP=Genetics OsteoArthritis and Progression. RS=Rotterdam study. KL=Kellgren-Lawrence score. *Drawn from the general population without consideration of their osteoarthritis status.
Table 1: Characteristics of study populations
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cartilage samples and analysed protein expression in 
cultured chondrocytes from samples of normal and 
osteoarthritic cartilage by use of western blotting. Full 
details are available in the appendix (p 6).
Statistical analysis
Statistical and imputational methods and Hardy-
Weinberg equilibrium are described in the appendix 
pp 2–5.
Role of the funding source
The sponsors of the study had no role in the study design, 
data collection, analysis or interpretation, or writing of 
the report. The corresponding authors had full access to 
all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
Genome-wide analysis showed an excess of signals 
compared with the null expectation of no association 
(genomic control infl ation factor λ1000=1·009; appendix 
p 74). In the main analysis (all cases of osteoarthritis vs 
population-based controls), 28 SNPs (representing 
12 independent signals) had a p value of less than 
1·0×10–⁵ compared with fi ve SNPs according to the null 
expectation (binomial test p=5·0×10–¹³; appendix p 12, 
p 36). We checked for false positives that were attributable 
to population stratifi cation by adjusting our analyses with 
the fi rst ten ancestry-informative principal components: 
our results did not change qualitatively (appendix p 6, 
p 75). New signals were not detected with HapMap-based 
imputation across the genome (appendix p 3, p 6, 
pp 60–61).
After large-scale replication, 71 (55%) of 129 signals 
taken forward had eff ects in the same direction as the 
discovery analysis on the basis of which they had been 
prioritised (appendix pp 76–81). All 26 SNPs selected for 
further follow-up had eff ects in the same direction 
(binomial p=2·98×10–⁸). Five of 26 loci had genome-wide 
signifi cance (p=5·0×10–⁸) and three were very close to 
this (table 2). Eff ect size estimates for seven of eight loci 
were lower in the replication analysis than in the 
discovery analysis (table 2), with the exception of one 
signal (ASTN2).
The most signifi cant signal was on chromosome 3 and 
was followed up by two SNPs in perfect linkage dis-
equilibrium (LD) with each other: rs11177 (allele A; 
fi gure A), a missense polymorphism within exon three of 
GNL3, coding for nucleostemin, and rs6976 (allele T; 
table 2), situated in the 3ʹ untranslated region (UTR) of 
the GLT8D1 gene. It was the only genome-wide signifi cant 
signal in the discovery GWAS before replication (table 2; 
appendix p 99) for all osteoarthritis and TJR strata (with 
stronger evidence for association in the TJR strata).
Chromo-
some
Position Nearest 
gene(s)
Eff ect 
allele
Stratum Discovery Replication Discovery and 
replication
Discovery and 
replication for analysis 
of all cases of 
osteoarthritis
Eff ect allele 
frequency 
in controls
Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value
rs6976* 3 52703844 GLT8D1 T TJR 0·37 1·16 
(1·11–1·22)
2·27×10¹⁰ 1·07 
(1·02–1·13)
7·79×10⁰³ 1·12 
(1·08–1·16)
7·24×10¹¹ 1·09 
(1·06–1·12)
6·56×10⁰⁹
rs11177* 3 52696345 GNL3 A TJR 0·38 1·16 
(1·11–1·22)
2·12×10¹⁰ 1·07 
(1·02–1·13)
7·70×10⁰³ 1·12 
(1·08–1·16)
1·25×10¹⁰ 1·09 
(1·06–1·12)
5·13×10⁰⁹
rs4836732 9 118306516 ASTN2 C THR–
female
0·47 1·19 
(1·10–1·28)
1·19×10⁰⁵ 1·23 
(1·12–1·34)
9·54×10⁰⁶ 1·20 
(1·13–1·27)
6·11×10¹⁰ 1·04 
(1·01–1·07)
1·56×10⁰²
rs9350591 6 76298247 FILIP1; 
SENP6
T Hip† 0·11 1·20 
(1·11–1·30)
2·49×10⁰⁶ 1·16 
(1·07–1·25)
1·64×10⁰⁴ 1·18 
(1·12–1·25)
2·42×10⁰⁹ 1·09 
(1·04–1·13)
2·78×10⁰⁴
rs10492367 12 27906237 KLHDC5; 
PTHLH
T Hip 0·19 1·18 
(1·11–1·27)
1·20×10⁰⁶ 1·11 
(1·04–1·18)
1·18×10⁰³ 1·14 
(1·09–1·20)
1·48×10⁰⁸ 1·06 
(1·03–1·10)
9·02×10⁰⁴
rs835487 12 103584897 CHST11 G THR 0·34 1·15 
(1·08–1·22)
3·26×10⁰⁶ 1·11 
(1·04–1·19)
9·32×10⁰⁴ 1·13 
(1·09–1·18)
1·64×10⁰⁸ 1·05 
(1·02–1·08)
6·22×10⁰⁴
rs12107036 3 191082854 TP63 G TKR–
female
0·52 1·23 
(1·13–1·35)
3·03×10⁰⁶ 1·17 
(1·05–1·30)
4·73×10⁰³ 1·21 
(1·13–1·29)
6·71×10⁰⁸ 1·05 
(1·02–1·08)
2·15×10⁰³
rs8044769‡ 16 52396636 FTO C Female 0·5 1·17 
(1·10–1·23)
5·98×10⁰⁸ 1·06 
(1·01–1·12)
2·01×10⁰² 1·11 
(1·07–1·15)
6·85×10⁰⁸ 1·07 
(1·04–1·10)
3·56×10⁰⁶
rs10948172 6 44885669 SUPT3H; 
CDC5L
G Male 0·29 1·17 
(1·10–1·26)
5·02×10⁰⁶ 1·11 
(1·04–1·19)
2·48×10⁰³ 1·14 
(1·09–1·20)
7·92×10⁰⁸ 1·08 
(1·05–1·12)
6·14×10⁰⁷
The details of the individual discovery and replication results of analyses of all cases of osteoarthritis are shown in the appendix p 99. TJR=total joint replacement. THR=total hip replacement. TKR=total knee 
replacement. arcOGEN=Arthritis Research UK Osteoarthritis Genetics. *Represent the same signal, r²=1; both were prioritised and showed similar p values and eff ect sizes before and after replication. †Analyses in 
which a subset of samples with osteoarthritis at the hip and knee are also included in the arcOGEN discovery set and in the UK replication set. ‡This signal was attenuated after adjustment for body-mass index, 
suggesting that the FTO locus exerts its eff ect on osteoarthritis through obesity.
Table 2: Association summary statistics for the eight replicating signals
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Figure: Regional association 
plots of replicating signals
Case–control association 
results (–log10 [p value]) for 
genotyped SNPs in the 
discovery set are plotted 
against genomic position 
(National Center for 
Biotechnology Information 
build 36) for the stratum in 
which the most signifi cant 
meta-analysis p value 
occurred. The index SNP is 
denoted by a purple diamond 
in the discovery set and by a 
purple square in the fi nal 
meta-analysis. The circles 
indicate association results of 
genotyped SNPs in the region; 
the colour refl ects the 
correlation coeffi  cient (r²) of 
each genotyped SNP with the 
index SNP estimated with the 
CEU HapMap II panel. 
Estimated recombination 
rates (in cM/Mb) are plotted in 
red. The region shown in the 
plots extends to either 500 kb 
upstream and downstream of 
the index SNP or until the next 
recombination hotspot if this 
lies further than a distance of 
500 kb. (A) Chromosome 3 
signal centred on rs6976 in 
total joint replacement. 
(B) Chromosome 9 signal 
centred on rs4836732 in 
female total hip replacement. 
(C) Chromosome 6 signal 
centred on rs9350591 in hip 
osteoarthritis. 
(D) Chromosome 12 signal 
centred on rs10492367 in hip 
osteoarthritis. 
(E) Chromosome 12 signal 
centred on rs835487 in total 
hip replacement. SNP=single 
nucleotide polymorphism. 
CEU=Utah residents with 
ancestry from northern and 
western Europe.
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All the remaining four genome-wide signifi cant 
signals emanated from hip-specifi c strata (table 2): 
rs4836732 (allele C; female total hip replacement 
[THR]) located within intron 18 of the ASTN2 gene 
(fi gure B; table 2); rs9350591 (allele T; hip osteoarthritis) 
located 38 kb upstream of FILIP1 and 70 kb upstream 
of SENP6 (fi gure C; table 2); rs10492367 (allele T; hip 
osteoarthritis) 59 kb downstream of KLHDC5 and 96 kb 
downstream of PTHLH (fi gure D; table 2); and rs835487 
(allele G; THR) located within intron two of CHST11 
(fi gure E; table 2).
Three additional signals lacked genome-wide signifi -
cance and therefore need to be interpreted with caution. 
Rs12107036 was associated with osteoarthritis in women 
with total knee replacement (TKR; allele G) and is located 
within intron 12 of TP63 (appendix p 70; table 2). 
Association with rs8044769 was strongest in the female 
osteoarthritis stratum (allele C), within intron 1 of FTO 
(appendix p 71; table 2). The fi nal signal was seen in the 
male osteoarthritis stratum at rs10948172 (allele G), 
situated in the vicinity of the SUPT3H gene (appendix 
p 72; table 2).
We investigated the eff ect of the defi nition of disease 
phenotype on the strength of association of the repli-
cating signals (table 2) by comparing the results of 
analyses of TJR-only cases (severe endpoint of disease) 
and all cases (TJR and radiography combined) for the 
stratum that had the lowest meta-analysis p value. We 
noted that, after large-scale replication, four signals 
(rs6976, rs4836732, rs835487, and rs12107036) were 
stronger in the TJR meta-analysis, one signal (rs9350591) 
was stronger in the meta-analysis of TJR and radiographic 
cases, and three signals (rs10492367, rs8044769, and 
rs10948172) were little changed (appendix p 100).
In the discovery set analyses of two types of controls—
population-based controls unselected for osteoarthritis 
(n=11 009) and osteoarthritis-free controls (n=1828)—we 
compared the strength of association of the three 
previously established osteoarthritis loci (appendix p 7, 
p 101) and the eight replicating signals (table 2). We 
noted that one signal (GDF5) was stronger in the 
analysis of osteoarthritis-free controls, whereas the 
other ten were stronger or similar in the analyses of 
population-based controls (appendix p 7, p 101, p 103). In 
the meta-analysis of discovery and replication sets, eff ect 
size estimates for the replicating loci were the same or 
smaller for all variants except one (CHST11) when we 
used disease-free controls, and all signals were statis-
tically stronger in the analyses of population-based 
controls (appendix p 7, p 104).
Because obesity is an established risk factor for 
osteoarthritis, we investigated whether any of the 
129 prioritised signals were attenuated after adjustment 
for body-mass index (BMI) with arcOGEN cases and 
disease-free TwinsUK control data (BMI data were not 
available for the population-based controls). Two SNPs 
(rs11107957 and rs2626053) showed greater than 
100-times increase in their p value (ie, became less 
signifi cant) after adjustment for BMI (appendix p 5, 
p 105). Rs804476 in FTO was the only replicating signal 
to be attenuated after BMI adjustment in the discovery 
GWAS, but we cannot exclude the possibility that BMI 
adjustment might have had an eff ect on the other 
variants in the replication cohorts. However, in the 
discovery scan, the association p value at the four 
remaining loci that had genome-wide signifi cance and 
the three signals just below this threshold were not 
aff ected by more than one order of magnitude after 
adjustment for BMI.
All the studied genes were expressed within osteo-
arthritic or control fracture neck-of-femur joint tissues 
(appendix p 6, p 108).
Immunohistochemical staining showed strong 
nucleolar expression of nucleostemin in cytospins of 
primary cultured chondrocytes from human articular 
cartilage derived from patients with osteoarthritis 
(appendix p 69), and a similar pattern of staining 
was seen in chondrocytes from frozen sections of 
osteoarthritic cartilage (appendix p 69). We measured 
levels of nucleostemin protein expression in cultured 
articular chondrocytes from fi ve controls and fi ve patients 
with osteoarthritis. Nucleostemin was barely detectable 
in cultured chondrocytes from controls but was clearly 
detectable in cultured chondrocytes from patients with 
osteoarthritis (appendix p 69). When nucleostemin 
expression was corrected for expression of the 
housekeeping gene β-actin, the upregulation of 
nucleostemin protein levels in osteoarthritis chon-
drocytes versus control chondrocytes was signifi cant 
(p=0·003; appendix p 69).
Discussion
We have identifi ed eight novel loci that are associated with 
the risk of developing osteoarthritis, fi ve of which 
surpassed genome-wide signifi cance and three that were 
just less than the threshold (panel). With the addition of 
previously established associations on chromosome 7q22, 
and in the GDF5 and MCF2L genes,6,7,9,11 the current total 
of osteoarthritis susceptibility loci in European populations 
is 11.
Our most signifi cant fi nding was in a gene-rich region 
of chromosome 3p21·1. Rs6976 lies within the 3ʹ UTR of 
GLT8D1 (glycosyltransferase 8 domain containing 1; 
fi gure A). Alterations in the expression of GLT8D1 could 
aff ect the glycosylation of cartilage proteins. Rs11177, in 
perfect LD with rs6976, encodes a missense variant 
(Arg→Gln) in the third exon of GNL3 (guanine nucleotide 
binding protein-like 3, or nucleostemin; fi gure A). GNL3 
is expressed in mesenchymal stem cells, from which 
chondrocytes are derived, and regulates the G1–S phase 
transition in stem cells.13–15 The function of GNL3 in bone 
and cartilage is not known because mice homozygous 
for deletion of GNL3 die on embryonic day 4.16 However, 
of interest is that nucleostemin protein levels were 
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substantially increased in cultured chondro cytes from 
patients with osteoarthritis compared with controls, 
raising the possibility that this gene might be functionally 
important in the pathogenesis of osteoarthritis.
Rs4836732 lies within the ASTN2 gene (astrotactin 2; 
fi gure B), which is highly expressed in the developing and 
adult brain. ASTN2 is a membrane protein that regulates 
surface levels of ASTN1 during neuronal migration.17 
Rs9350591 lies between the FILIP1 (fi lamin A interacting 
protein 1) and SENP6 (sentrin specifi c peptidase 6) genes 
(fi gure C). COL12A1 (collagen, type XII, alpha 1), the 
product of which is found in articular cartilage,18 lies at a 
distance of about 326 kb. Rs10492367 is located between 
the KLHDC5 (Kelch domain containing 5) and PTHLH 
(parathyroid hormone-like hormone) genes (fi gure D). 
Parathyroid hormone-related protein (PTHrP)  regulates 
endochondral bone develop ment. Results from studies of 
Pthrp–/– mice showed that animals who survived gestation 
had accelerated diff erentiation of chondrocytes in bone.19
Rs835487 is located in the CHST11 (carbohydrate 
sulfotransferase 11) gene (fi gure E), which encodes a 
Golgi enzyme that catalyses the transfer of sulphate 
groups to the 4-O position of chondroitin and dermatan 
sulphate, important components of cartilage proteo-
glycans.20 CHST11 has a role in skeletal development, 
signalling pathways, and cancer progression.21 It has 
substantially higher expression in osteoarthritic cartilage 
than in normal articular cartilage22 and mice that are null 
for this gene have a disorganised growth plate, accel-
erated chondrocyte diff erentiation, altered patterns of 
signalling with transforming growth factor β and bone 
morphogenetic protein, and a fi brillated cartilage extra-
cellular matrix that is characteristic of osteoarthritic 
cartilage.23 Chondroitin sulfate is used as a symptomatic, 
slow-acting drug for osteoarthritis, recom mended by the 
latest Osteoarthritis Research Society International treat-
ment guidelines, but evidence for its eff ectiveness 
remains controversial.24
Rs12107036 lies within intron 12 of the TP63 gene 
(encoding tumour protein p63; appendix p 70). p63 null 
mice have serious defects in their limb, craniofacial, 
and epithelial development.25,26 Rs8044769 lies within 
FTO (appendix p 71), a well established locus that is 
associated with fat mass and obesity27 and is in partial LD 
(r²>0·6) with the reported index BMI-associated SNPs. 
This signal was attenuated after adjustment for BMI, 
suggesting that the FTO gene exerts its eff ect 
on osteoarthritis through obesity. Rs10948172 occurs 
between CDC5L (CDC5 cell division cycle 5-like) and 
SUPT3H genes (suppressor of Ty3 homologue; appendix 
p 72). At a distance of 500 kb, but possibly containing 
SNPs correlated with rs10948172, is the RUNX2 (runt-
related transcription factor 2) gene, which encodes a 
protein that is essential for osteoblast diff erentiation28 
and skeletal morphogenesis.29 RUNX2 was identifi ed in 
peripheral blood expression profi les as a possible 
biomarker for bone metabolism in arthritis.30
The results of our study draw attention to three 
important issues with respect to design and analysis that 
are of relevance to GWAS investigations of complex 
disease: defi nition of signifi cant association in view of 
several correlated stratifi ed analyses; eff ect of phenotype 
homogeneity and misclassifi cation; and allowing for 
power constraints when seeking replication of previously 
identifi ed loci. First, we analysed several specifi c non-
independent phenotypes in addition to the main analysis 
of all osteoarthritis cases versus controls so as to increase 
power to detect signals specifi c for joint, sex, or disease 
severity. Compelling evidence suggests that joint-specifi c 
genetic factors play a part in the pathogenesis of 
osteoarthritis31 and that the familial concordance for hip 
and knee osteoarthritis is greater in surgically defi ned 
than in radiographically defi ned disease.32–34 The results of 
these reports, in addition to the signifi cant diff erences 
reported in the prevalence of osteoarthritis between 
skeletal sites, the sexes, and radiographic versus sympto-
matic disease,35 underpin our decision to stratify our data 
by site of osteoarthritis (hip or knee), sex, sex with site, 
and the two modes of osteoarthritis defi nition (radio-
graphic and joint replace ment) that we have used. That 
most of the loci we have identifi ed are associated with 
osteoarthritis at a par ticular joint site provides genetic 
Panel: Research in context
Systematic review
We searched PubMed for articles in English with a combination of the terms 
“osteoarthritis” and “genetic” to identify reports of loci encoding susceptibility for 
osteoarthritis. We then focused on those in which genetic associations had been 
identifi ed with a compelling level of signifi cance (p≤5×10⁸) and with replication. This 
gave three loci: GDF5, 7q22, and MCF2L. These formed the basis by which we put our 
GWAS results into context. In our search we also took advantage of the extensive 
knowledge of several of the arcOGEN investigators who have published many reviews 
about the genetics of osteoarthritis.
Interpretation
We identifi ed eight novel genetic risk loci for osteoarthritis. Two are close to functional 
candidate genes that suggest clinical implications for osteoarthritis. CHST11 codes for an 
enzyme that modulates cartilage proteoglycan, with proteoglycan modulation being an 
active area of osteoarthritis therapeutic development; nutraceutical compounds, such as 
chondroitin sulfate, have been extensively studied. Although the evidence of effi  cacy of 
such compounds in relieving signs and symptoms of osteoarthritis is weak, our results 
suggest that alternate therapeutic approaches acting on this same pathway could be 
clinically benefi cial. Novel anabolic treatments for osteoporosis have been developed with 
peptide fragments based on parathyroid hormone, and our results suggest that 
investigating these compounds in the treatment of osteoarthritis, or assessing endpoints 
of osteoarthritis in previous clinical trials of parathyroid hormone, would now be sensible. 
Furthermore, the association with FTO draws attention to the interplay between 
bodyweight and osteoarthritis, and emphasises existing clinical advice that loss of excess 
bodyweight is a clinical recommendation for symptom relief and avoidance of 
osteoarthritis. Our demonstration that osteoarthritis risk loci are on the whole specifi c to 
either the hip or the knee informs the clinician that the pathophysiological process of this 
chronic disease is likely to have joint-specifi c components that need to be borne in mind 
when developing treatment regimens.
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evidence that the aetiopathogenesis of osteoarthritis is not 
uniform, but that joint-specifi c risk factors are in opera-
tion. A conservative Bonferroni correction, assum ing the 
inde pendence of these highly correlated specifi c pheno-
types, would artifi cially move the p-value threshold 
of declaring genome-wide signifi cant association to 
2·08×10–⁹.36 In this work, we draw attention to eight novel 
associations with osteoarthritis based on a combination of 
statistical evidence of association, corroborative evidence 
from large-scale replication, and biological insights 
aff orded by the replicating loci that we noted (eg, PTHLH 
and CHST11, both excellent biological candi dates, would 
not have surpassed the more stringent threshold).
Second, we accrue evidence that, in general, analyses of 
patients ascertained by the more stringent criterion of 
arthroplasty have power advantages over those including 
radiographically diagnosed cases, emphasising the value 
of patient phenotype homogeneity (appendix p 100). All 
eight loci reported in this study were prioritised on 
the basis of analyses of osteoarthritis-status-agnostic 
controls, indicating that the large increase in sample size 
aff orded by the use of population-based controls might 
have power advantages despite potential misclassifi cation 
(appendix pp 101–04).
Third, we assessed evidence for association at the three 
previously reported osteoarthritis loci in our discovery 
GWAS. We detected signals with p=0·002 to p=6×10–⁴ for 
the chromosome 7 and MCF2L loci, but little evidence 
for association at GDF5. These results are in keeping 
with fi ndings in other complex disease discovery GWAS37 
and can be ascribed to a combination of power, stochastic 
variation in allele frequency estimates, and the absence 
of the index variant from the genotyping platform 
(appendix p 7, p 101).
We have studied common variants and therefore the 
fi ndings of our report cannot be used to estimate the 
eff ect that rarer variants might have on causing osteo-
arthritis. Further, although our discovery sample size of 
7410 cases is the largest yet used for osteoarthritis, the 
sample was stratifi ed; an analysis of larger stratifi ed 
subsets might show additional associated loci. In our 
study, we focused on Europeans and it will be of great 
interest to assess whether these loci have global relevance 
to osteoarthritis risk through similar studies of non-
European cohorts with osteoarthritis.
All eight identifi ed loci are represented by common 
SNPs (minor allelic frequency 0·11–0·50) and have small 
eff ect sizes (allelic ORs from 1·11 to 1·21). In keeping 
with other common complex trait studies, these fi ndings 
indicate that common SNPs with large eff ect sizes are not 
likely to have a role in the pathogenesis of osteoarthritis. 
Association at the index SNPs reported here does not 
imply causality. Functional studies will be necessary to 
pinpoint the precise func tional variants. The eight signals 
identifi ed in this study have a combined sibling recur-
rence risk (λs) estimate of 1·028 and account for only a 
small fraction of familial clustering of osteoarthritis. This 
outcome leads us to advocate larger-scale sample sizes, 
typically achieved through GWAS meta-analysis eff orts in 
complex traits. The arcOGEN GWAS is the largest study 
of osteoarthritis genetics so far and has suffi  cient power 
to detect slight eff ects at common loci at the genome-
wide signifi cance level (eg, 80% power to detect an allele 
with frequency 0·35 and allelic OR of 1·15). We have 
established novel loci represented by common SNPs that 
confer a slight risk for osteoarthritis and are associated 
with the clinically important phenotype of TJR. These 
results provide a basis for functional studies to identify 
the underlying causative variants, biological networks, 
and molecular cause of osteoarthritis.
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